Cancer stem cells (CSCs) are subpopulations of undifferentiated cancer cells within the
tumor bulk that are responsible for tumor initiation, recurrence and therapeutic resistance …

Exploration of tumor immunity leads to the development of immune checkpoint inhibitors and
cell-based immunotherapies which improve the clinical outcomes in several tumor types …

The rapid development and remarkable success of checkpoint inhibitors have provided
significant breakthroughs in cancer treatment, including hepatocellular carcinoma (HCC) …

Background Locoregional therapy combined with systemic therapy can further improve the
prognoses for HCC. However, the efficacy of TACE combined with ICIs and TKIs for HCC …

Cancer is a complex disease and cancer cells typically harbor multiple genetic and
epigenetic alterations. Large-scale sequencing of patient-derived cancer samples has …

Angiogenesis, a hallmark of cancer, is induced by vascular endothelial growth factor–A
(hereafter VEGF). As a result, anti-VEGF therapy is commonly used for cancer treatment …

Simple Summary There is a growing body of literature demonstrating high cancer drug costs
relative to the benefits provided to patients treated on a large scale. We examined the cost …

Hepatocellular carcinoma (HCC) is the most common liver cancer and is among the leading
causes of cancer-related death worldwide. There is no reliable biomarker for the early …

A novel gold nanoparticle (Do-AuNP) was successfully synthesized from water extracts of
traditional Chinese medicine Dendrobium officinale (DO) without using any extra chemicals …

Hepatocellular carcinoma (HCC) is a common primary liver cancer with∼ 750,000 annual
incidence rates globally. PGE2, usually known as a pro-inflammatory cytokine, is over …